You are here

  • Home
  • Archive
  • Volume 54, Issue 11
  • Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment

Article metrics

Article menu

Download PDFPDF

XML
Therapeutics
Original article
Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment

 

Online download statistics by month:

Online download statistics by month: July 2017 to March 2023

AbstractFullPdf
Jul 201717518022
Aug 2017329372171
Sep 2017141141103
Oct 201732435676
Nov 201716116169
Dec 2017979933
Jan 2018999951
Feb 2018988821
Mar 2018636420
Apr 2018828245
May 2018899224
Jun 2018737331
Jul 2018717129
Aug 2018656548
Sep 2018919130
Oct 201813713739
Nov 201812112124
Dec 201813013017
Jan 2019959530
Feb 201910710428
Mar 2019393718
Apr 2019171424
May 2019555024
Jun 2019363521
Jul 2019373717
Aug 2019353218
Sep 2019262415
Oct 2019474423
Nov 2019252411
Dec 201920207
Jan 2020494618
Feb 2020302914
Mar 2020353421
Apr 2020151516
May 202022217
Jun 2020211610
Jul 2020372739
Aug 2020343013
Sep 202027253
Oct 2020252421
Nov 2020232019
Dec 2020191614
Jan 2021282511
Feb 202110711
Mar 2021363313
Apr 202113105
May 2021272710
Jun 2021272412
Jul 2021302613
Aug 2021322819
Sep 2021424114
Oct 2021393928
Nov 2021414024
Dec 202149467
Jan 2022252214
Feb 202233328
Mar 2022605314
Apr 2022383113
May 2022726816
Jun 2022686612
Jul 202243445
Aug 2022777312
Sep 2022524821
Oct 2022565317
Nov 2022575419
Dec 2022454311
Jan 2023554913
Feb 2023515013
Total432842731639